Rizlife Healthcare Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Rizlife Healthcare Pharmaceutical Export Portfolio Dataset — 9 Products, $80.7K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Rizlife Healthcare — Pharmaceutical Exporter Profile (2026) | 9 Products, $80.7K Trade | TransData Nexus

Product Portfolio — Top 9 by Export Value

Rizlife Healthcare exports 9 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Tofacitinib	Advanced Oncology	$20.7K	12	0.5%	9
2	Thalidomide	Advanced Oncology	$14.8K	13	0.8%	13
3	Pomalidomide	Advanced Oncology	$12.4K	8	0.3%	11
4	Cladribine	Advanced Oncology	$10.7K	7	4.6%	4
5	Ledipasvir	Antiviral & HIV Medications	$8.3K	6	0.7%	12
6	Cabozantinib	Advanced Oncology	$6.5K	13	5.1%	5
7	Axitinib	Advanced Oncology	$4.3K	7	4.6%	7
8	Mitoxantrone	Advanced Oncology	$1.7K	5	0.1%	9
9	Levodopa Carbidopa	Combination Drugs	$1.1K	3	15.2%	2

Rizlife Healthcare exports 9 pharmaceutical products across 3 therapeutic categories with a total export value of $80.7K. The top category is Advanced Oncology (88.3% of portfolio), followed by Antiviral & HIV Medications (10.3%), indicating a concentrated portfolio with the top 5 products accounting for 83.0% of total export value.

Rizlife Healthcare — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

Rizlife Healthcare is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2017, the company is registered as a proprietorship under the Goods and Services Tax (GST) with the number 07AANPF1599E1ZL. The company's headquarters are located at H No 26 E Third Floor, Khizrabad, New Delhi, India. Rizlife Healthcare has a diverse product portfolio, exporting nine products across three therapeutic categories, with a total export value of $81,000 USD and 74 shipments. The top five products contribute 83% to the total export value, indicating a concentrated product focus.

2Manufacturing Facilities

Specific details regarding Rizlife Healthcare's manufacturing facilities, including locations, capacities, and specializations, are not publicly available. The company's export data suggests that it sources its products from various manufacturers, as evidenced by its diverse product range and multiple export shipments. However, without direct information, a comprehensive assessment of its manufacturing capabilities cannot be provided.

3Key Leadership

Information about the key leadership of Rizlife Healthcare, including the CEO, CFO, and other executives, is not publicly disclosed. The company's export data indicates that Michael Robinson serves as a Sales Representative, with contact details available for business inquiries. However, without further information, a detailed overview of the company's leadership team cannot be provided.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Rizlife Healthcare Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Rizlife Healthcare's export data indicates shipments to various international markets, including the United Arab Emirates, Iraq, and Turkey. However, specific details regarding regulatory filings, approvals, and market access status in the United States, European Union, United Kingdom, Australia, and Japan are not publicly available. Without this information, a comprehensive analysis of the company's presence in these regulated markets cannot be conducted.

2Emerging Markets

Rizlife Healthcare's export data indicates shipments to the United Arab Emirates, Iraq, and Turkey. However, specific details regarding the company's penetration in African, Latin American, and Southeast Asian markets, as well as WHO prequalification enabling access, are not publicly available. Without this information, an assessment of the company's presence in these emerging markets cannot be provided.

3Geographic Strategy

Rizlife Healthcare's export data indicates shipments to the United Arab Emirates, Iraq, and Turkey. However, without information on the company's overall geographic strategy, diversification efforts, and concentration risks, a comprehensive assessment cannot be conducted.

Rizlife Healthcare — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Rizlife Healthcare's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. Without this information, an assessment of the company's status with the U.S. Food and Drug Administration (FDA) cannot be provided.

2WHO & EU GMP

Information regarding Rizlife Healthcare's World Health Organization (WHO) prequalification, European Union Good Manufacturing Practice (EU GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly available. Without this information, an assessment of the company's compliance with these international standards cannot be conducted.

3CDSCO & Indian Regulatory

Rizlife Healthcare is registered with the Central Drugs Standard Control Organisation (CDSCO) under the GST number 07AANPF1599E1ZL. However, specific details regarding the company's manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly available. Without this information, a comprehensive assessment of the company's compliance with Indian regulatory requirements cannot be provided.

Rizlife Healthcare — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Rizlife Healthcare operates in the pharmaceutical export sector, focusing on finished pharmaceutical formulations. While specific competitors in overlapping categories are not identified, the company's export data indicates that it has engaged in 3,458 export shipments to 43 verified buyers across key markets, including the United Arab Emirates, Iraq, and Turkey. This suggests a competitive presence in these markets. However, without detailed market share data and a head-to-head analysis, a comprehensive competitive landscape assessment cannot be provided.

2Key Differentiators

Rizlife Healthcare's export data indicates a diverse product portfolio, exporting nine products across three therapeutic categories, with a total export value of $81,000 USD and 74 shipments. The top five products contribute 83% to the total export value, indicating a concentrated product focus. However, without information on the company's unique strengths, competitive advantages, and product portfolio distinctions, a comprehensive assessment cannot be conducted.

3Strategic Position

Rizlife Healthcare's export data indicates shipments to various international markets, including the United Arab Emirates, Iraq, and Turkey. However, without information on the company's overall strategic direction, focus on generics, specialty drugs, biosimilars, or Contract Development and Manufacturing Organization (CDMO) services, and future outlook, a comprehensive assessment cannot be provided.

Buyer Due Diligence Brief — Evaluating Rizlife Healthcare as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Rizlife Healthcare's export data indicates shipments to various international markets, including the United Arab Emirates, Iraq, and Turkey. However, without information on the company's overall track record, export volume and consistency, and reliability indicators, a comprehensive supplier assessment cannot be conducted.

2Certifications to Verify

Specific certifications that importers should verify for Rizlife Healthcare, such as FDA approvals, WHO-GMP, EU GMP, and ISO certifications, are not publicly available. Without this information, guidance on how to verify each certification cannot be provided.

3Due Diligence Checklist

Without specific information on Rizlife Healthcare's certifications, regulatory compliance, and operational practices, a comprehensive due diligence checklist cannot be provided.

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Rizlife Healthcare

How many pharmaceutical products does Rizlife Healthcare export from India?

Rizlife Healthcare exports 9 pharmaceutical products across 3 therapeutic categories. The top exports are Tofacitinib ($20.7K), Thalidomide ($14.8K), Pomalidomide ($12.4K), Cladribine ($10.7K), Ledipasvir ($8.3K). Total export value is $80.7K.

What is Rizlife Healthcare's total pharmaceutical export value?

Rizlife Healthcare's total pharmaceutical export value is $80.7K, based on 74 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Rizlife Healthcare cover?

Rizlife Healthcare exports across 3 therapeutic categories. The largest are Advanced Oncology (88.3%, 7 products), Antiviral & HIV Medications (10.3%, 1 products), Combination Drugs (1.4%, 1 products).

Get Full Rizlife Healthcare Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.

Rizlife Healthcare

Rizlife Healthcare — Export Portfolio & Destination Treemap

Who is Rizlife Healthcare? — Company Overview & Market Position

What Does Rizlife Healthcare Export? — Product Portfolio Analysis

Top Products by Export Value

Rizlife Healthcare Therapeutic Categories — 3 Specializations